



(11) **EP 2 034 975 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 9/50 (2006.01)**

(86) International application number:  
**PCT/US2007/014282**

(48) Corrigendum issued on:  
**16.05.2012 Bulletin 2012/20**

(87) International publication number:  
**WO 2007/149438 (27.12.2007 Gazette 2007/52)**

(45) Date of publication and mention  
of the grant of the patent:  
**11.04.2012 Bulletin 2012/15**

(21) Application number: **07809672.4**

(22) Date of filing: **19.06.2007**

(54) **PHARMACEUTICAL COMPOSITIONS**  
**PHARMAZEUTISCHE ZUSAMMENSETZUNGEN**  
**COMPOSITIONS PHARMACEUTIQUES**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE**  
**SI SK TR**

(30) Priority: **19.06.2006 US 814949 P**

(43) Date of publication of application:  
**18.03.2009 Bulletin 2009/12**

(60) Divisional application:  
**12153443.2**

(73) Proprietor: **Alpharma Pharmaceuticals, LLC**  
**Bridgewater, NJ 08807 (US)**

(72) Inventors:  
• **MATTHEWS, Frank**  
**Bridgewater, NJ 08807 (US)**

- **BOEHM, Garth**  
**Bridgewater, NJ 08807 (US)**
- **TANG, Lijuan**  
**Bridgewater, NJ 08807 (US)**
- **LIANG, Alfred**  
**Bridgewater, NJ 08807 (US)**

(74) Representative: **Lawrence, Malcolm Graham et al**  
**avidity IP**  
**Merlin House**  
**Falconry Court**  
**Baker's Lane**  
**Epping, Essex CM16 5DQ (GB)**

(56) References cited:  
**EP-A- 0 271 193 WO-A-2005/055981**  
**WO-A-2005/081825 WO-A-2007/145863**  
**US-A- 5 958 459 US-A1- 2003 004 177**  
**US-A1- 2003 124 185 US-A1- 2004 254 208**

**EP 2 034 975 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).